Tag Archives: Acadia

Acadia Outsources Compassion and Math

On their quarterly call, Acadia Pharmaceuticals announced the pricing for Nuplazid, freshly approved by the FDA for the treatment of Parkinsonian psychosis (PDP). The price has been set at $1950 per month, about $23,400 per year. A quick scan of … Continue reading

Posted in Big Pharma, BioFollies, Biotech | Tagged , , | 1 Comment

New Literacy Requirement for Physicians

“FDA has approved a brand name change for the antidepressant Brintellix (vortioxetine) to decrease the risk of prescribing and dispensing errors resulting from name confusion with the blood-thinning medicine Brilinta (ticagrelor). The new brand name of the drug will be … Continue reading

Posted in BioFollies | Tagged , , , , | Leave a comment

Passing for Analysis

Occasionally, the general financial press comes up with a comparison or concept that is amusingly obtuse, but it’s less amusing when one considers the likelihood that this reflects the kind of superficial analysis that can drive investor sentiment, and that … Continue reading

Posted in Muddled Media | Tagged | Leave a comment

Acadia and the FDA

In the upcoming May issue of NeuroPerspective, we will be including some commentary about institutional and regulatory rituals which endure without clear justification–or at the very least,  deserve some reconsideration. This comes in the wake of having recently had the … Continue reading

Posted in Biotech | Tagged , , , | 1 Comment